Published: March 30, 2021
BioNTech and Pfizer raised this year's production target for their covid-19 vaccine to as many as 2.5 billion doses, with the biotech's chief executive predicting a version of the shot that can be stored in refrigerators will be ready within months.
Published: March 25, 2021
Hong Kong and Macao temporarily suspended covid-19 vaccines manufactured by BioNTech because of a packaging defect, dealing a blow to inoculation drives seen as key to reviving the cities' pandemic-battered economies.
Published: March 11, 2021
BioNTech could have capacity to make 3 billion doses of covid-19 vaccine with U.S. partner Pfizer next year, the German company's chief executive officer said, making their pioneering shot far more widely available around the world.
Published: February 23, 2021
The Pfizer Inc. and BioNTech SE coronavirus vaccine appeared to stop the vast majority of recipients in Israel becoming infected, providing the first real-world indication that the immunization will curb transmission of the coronavirus.
Published: January 05, 2021
Pfizer Inc. and BioNTech SE offered to supply South Africa with their coronavirus vaccine at a discounted $10 a dose, yet the president's office still described the cost as prohibitive, according to a person familiar with the talks.
Published: December 22, 2020
Pfizer Inc. partner BioNTech SE is pursuing all its options to make more coronavirus vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German firm's chief executive officer.
Published: December 11, 2020
WASHINGTON - Federal advisers endorsed the Pfizer-BioNTech coronavirus vaccine on Thursday, making it all but certain the Food and Drug Administration will authorize the vaccine on an emergency basis within hours or days, kicking off an unprecedented effort to inoculate enough Americans to stop a rampaging pandemic.